PDF(745 KB)
Role of tirofiban combined with anisodamine injection in protecting myocardial function recovery and endothelial function in patients with STEMI after PCI
ZHANG Xiaojing, LIU Huiliang, ZHU Lin, ZHANG Jiao, YU Hong, LI Yi
Medical Journal of the Chinese People Armed Police Forces ›› 2020, Vol. 31 ›› Issue (3) : 203-206.
PDF(745 KB)

PDF(745 KB)
Role of tirofiban combined with anisodamine injection in protecting myocardial function recovery and endothelial function in patients with STEMI after PCI
ObjectiveTo investigate the protective role of tirofiban combined with anisodamine injection in myocardial function recovery and endothelial function in patients with STEMI after PCI.Methods One hundred and sixteen cases of STEMI patients treated in our hospital between July 2016 and February 2018 were selected as the subjects. Using the simple random method, the patients were divided into the control group and the observation group. Both groups were treated with PCI, but the control group was given tirofiban, while the observation group received tirofiban + anisodamine. The changes of myocardial reperfusion, cardiac function, vascular endothelial injury markers and adverse cardiovascular events were compared between the two groups before and after treatment.Results The 2 h ST segment drop rate, cTFC and the myocardial perfusion grade of the observation group were better than those of the control group (P<0.05). The left ventricular end-diastolic diameter (LVEDD), left ventricular ejection force (LVEF) and left ventricular end-diastolic diameter (LVEDD) were improved after operation in both groups (P<0.05). At T1 and T2, the LVEDD and LVEF of the observation group were better than those of the control group (P<0.05). After treatment, the levels of vascular endothelial growth factor and ET-1 in the two groups were lower, but the levels of NO were higher (P<0.05). After treatment, the levels of vascular endothelial growth factor and ET-1 in the observation group were lower than those in the control group(荒唐的表达). The incidence of adverse cardiovascular events within 6 months after PCI was 17.24% (10/58) in the observation group and 3.45% (2/58) in the control group.Conclusions Tirofiban combined with anisodamine injection can boost myocardial perfusion in patients with STEMI, improve cardiac function, protect vascular endothelium and reduce the risk of adverse cardiovascular events.
tirofiban / anisodamine / acute myocardial infarction / percutaneous coronary intervention
/
| 〈 |
|
〉 |